ppharm

Педиатрическая фармакология

Pediatric pharmacology

1727-57762500-3089

Издательство «ПедиатрЪ»

10.15690/pf.v12i2.1285

ppharm-11

Research Article

В ПРАКТИКУ ПЕДИАТРА

For Pediatricians' Practice

ОПЫТ ПРИМЕНЕНИЯ ИНГИБИТОРА ИНТЕРЛЕЙКИНА 1 КАНАКИНУМАБА У ПАЦИЕНТОВ С АУТОВОСПАЛИТЕЛЬНЫМИ ЗАБОЛЕВАНИЯМИ

CASE OF USING THE INHIBITOR OF INTERLEUKIN 1 CANACINUMAB IN PATIENTS WITH AUTO INFLAMMATORY DISEASES

Салугина

С. О.

Salugina

S. O.

pafon1@yandex.ru

Фёдоров

Е. С.

Fedorov

E. S.

pafon1@yandex.ru

Кузьмина

Н. Н.

Kuz'mina

N. N.

pafon1@yandex.ru

Захарова

Е. Ю.

Zakharova

E. Yu.

pafon1@yandex.ru

Научно-исследовательский институт ревматологии имени В.А. Насоновой, Москва, Российская ФедерацияРоссияNasonova Rheumatology Scientific Research Center, Moscow, Russian FederationRussian Federation

Медико-генетический научный центр, Москва, Российская ФедерацияРоссияMedico-Genetic Scientific Center, Moscow, Russian FederationRussian Federation

2015

19042015

122

Педиатрическая фармакология

209217

2015

Салугина С.О., Фёдоров Е.С., Кузьмина Н.Н., Захарова Е.Ю.

Salugina S.O., Fedorov E.S., Kuz'mina N.N., Zakharova E.Y.

Данная работа распространяется под лицензией Creative Commons Attribution 4.0.

This work is licensed under a Creative Commons Attribution 4.0 License.

https://www.pedpharma.ru/jour/article/view/11

Основным медиатором воспаления для многих аутовоспалительных заболеваний (АВЗ) является интерлейкин 1β (IL 1β). Криопиринассоциированные периодические синдромы (CAPS) стали первыми заболеваниями, при которых с высокой степенью доказательности была показана эффективность ингибиторов IL 1. Канакинумаб (полностью человеческие моноклональные антитела к IL 1β) с 2011 г. зарегистрирован в Российской Федерации для лечения CAPS. В настоящее время проводятся исследования по оценке эффективности и переносимости ингибиторов IL 1 у пациентов с другими АВЗ. Накопленный практический опыт и немногочисленные рандомизированные контролируемые исследования демонстрируют успешное применение ингибиторов IL 1 у колхицинрезистентных пациентов с семейной средиземноморской лихорадкой с купированием воспалительных атак и снижением острофазовой активности, а также у больных с другими моногенными (TRAPS, HIDS и др.) и мультифакториальными патологиями (системный ювенильный артрит, болезнь Стилла у взрослых, подагра и др.). Применение ингибиторов IL 1, в частности канакинумаба, у пациентов с различными АВЗ, по данным российских и зарубежных исследований, показало хорошую переносимость и высокую эффективность препарата у всех больных независимо от возраста. Таким образом, канакинумаб, благодаря своим терапевтическим возможностям, имеет широкие перспективы в плане облегчения течения болезни, улучшения выживаемости, качества жизни и общего прогноза.

Interleukin 1 (IL 1) is the main mediator for many auto inflammatory diseases (AID). Cryopyrin-associated periodic syndromes (CAPS) became the first diseases, for which the efficacy of IL 1 inhibitors was shown with a high degree of evidence. Canacinumb (totally human monoclonal antibodies to IL 1 is registered in Russia since 2011 for treating CAPS. At the moment research is being conducted to evaluate the efficacy and tolerance to IL 1 inhibitors in patients with other AIDs. The accumulated experience and scarce randomizedcontrolled studies demonstrate a successful usage of IL 1 inhibitors in colchicine-resistant patients with family Mediterranean fever with the cupping of inflammation attacks, reducing the acute phase activity and also in patients with other monogenic (TRAPS, HIDS and others) and multifactorial pathologies (systemic juvenile arthritis, Stilk disease in adults, gout etc.). Using the IL 1 inhibitors, especially canacinumab, in patients with different AIDs has shown good tolerance and a high efficacy in all patients with no correlation to the age, according to Russian and world research. Thus, canacinumab, thanks to its therapeutic abilities, has broad perspectives in terms of lightening the disease course, improving survival, life quality and the overall prognosis.

криопиринассоциированные периодические синдромыпериодический синдромассоциированный с мутацией гена рецептора фактора некроза опухолилечениеканакинумабингибиторы IL 1

cryopyrin-associated periodic syndromesperiodic syndromeassociated with the tumor necrosis factor receptor gene mutationtreatmentcanakinumabIL 1inhibitors

References1

Federici S., Gattorno M. A practical approach to the diagnosis of autoinflammatory diseases in childhood. Best Practice and Research Clin. Rheumatol. 2014; 28: 263–276.

Fietta P. Autoinflammatory disease: the hereditary periodic fever syndromes. Acta Biol. Ateneo Parmense. 2004; 75: 92–99.

Kuz'mina N.N., Salugina S.O., Fedorov E.S. Autovospalitel'nye zabolevaniya i sindromy u detei. Uchebno–metodicheskoe posobie [Autoinflammatory Diseases and Syndromes in Children. Textbook]. Moscow, IMA–PRESS, 2012. 104 p.

Dinarello C. Bloking IL–1 in systemic inflammation. JEM. 2005; 201: 1355–1359.

Simon A., van der Meer J.W.S. Pathogenesis of familial periodic fever syndromes or hereditary inflammatory syndromes. Am. J. Physiol. Regul. Integr. Comp. Physiol. 2007; 292: 86–98.

Goldbach–Mansky R., Kastner D.L. Autoinflammation: The prominent role of IL-1 in monogenic autoinflammatory diseases and implication for common illnesses. J. Allergy Clin. Immunol. 2009; 124: 1141–1151.

Dinarello C. A Signal for the Caspase–1 Inflammasome Free of TLR. Immun. 2007; 26: 383–385.

Drenth J.P.H., van der Meer W.M. The Inflammasome A Linebacker of Innate Defense. N. Engl. J. Med. 2006; 355: 730–732.

Federici S., Martini A., Gattorno M. The central role of anti-IL-1 blockade in the treatment of monogenic and multifactorial autoinflammatory diseases. Frontiers un Immunology. 2013; 4: 351.

Gattorno M. Autoinflammatory diseases in children. Voprosy sovremennoi pediatrii = Current pediatrics. 2014; 13: 55–64.

Ter Haar N., Lachmann H.J., Ozen S., Woo P., Uziel Y., Modesto C., Kone–Paut I. Treatment of autoinflammatory disease: results from the Eurofever Registry and a literature review. Ann. Rheum Dis. 2013; 72: 678–685.

URL: http://fmf.igh.cnrs.fr/ISSAID/infevers/index.php (available: 14.04.2015).

Kuijk L.M., Hoffman H.L., Neven B., Frenkel J. Episodic Autoinflammatory Disorders in Children. In Handbook of Systemic Autoimmune Disease. Pediatrics in Systemic Autoimmune Disease. Eds. R. Cimas, Lehman T. New York: Elsevier Saunders. 2008. V. 6. P. 119–135.

Feldman J. Prieur A.M., Quartier P., Berquin P., Certain S., Cortis E., Teillac–Hamel D., Fischer A., de Saint Basile G. Chronic infantile neurological cutaneouse and articular syndrome is caused by mutations in CIAS1, a gene highly expressed in polymorphonucleare cells and chondrocytes. Am. J. Hum. Genet. 2002; 71: 198–203.

Hoffman H.M.. Mueller J.L., Broide D.H., Wanderer A.A., Kolodner R.D. Mutation of a new gene encoding a putative pyrine like protein causes familial cold autoinflammatory syndrome and Muckle–Wells syndrome. Nat. Genet. 2001; 29: 915–921.

Cuisset L., Jeru I., Dumont B., Fabre A., Cochet E., Bozec J., Delpech V., Amselem S., Touitou I., and the French CAPS study group. Mutation in the autoinflammatory cryopyrin associated periodic syndrome gene: epidemiological study and lessons from eight years of genetic analysis in France. Ann. Rheum. Dis. 2011; 70: 495–499.

Barron K., Athreya B., Kastner D. Periodic fever syndromes and other inherited autoinflammatory diseases. In: Textbook of pediatric rheumatology. Ed. Cassidy J.T. New York: Elsevier Saunders. 2011. Р. 642–660.

Kitley J.L., Lachmann H.J., Pinto A., Ginsberg L. Neurologic manifestations of the cryopyrin-associated periodic syndrome. Neurology. 2010; 2074 (16): 1267–1270.

Yu J.R. and Leslie K. S. Cryopyrin Associated Periodic Syndrome: An Update on Diagnosis and Treatment Response. Curr. Allergy Asthma Rep. 2011; 11 (1): 12–20.

Federico G., Rigante D., Pugliese A.L., Ranno O., Catania S., Stabile A. Etanercept induces improvement of arthropathy in chronic infantile neurological cutaneous articular (CINCA) syndrome. Scand. J. Rheumatol. 2003; 32: 312–314.

Kuemmerle–Deschner J., Haug I. Canakinumab in patients with cryopyrin associated periodic syndrome: an update for clinicians. Ther. Adv. Musculoskel Dis. 2013; 5 (6): 315–319.

Toker O., Hashkes P.J. Critical appraisal of canakinumab in the treatment of adults and children with cryopyrin associated periodic syndrome (CAPS). Biologics: Targets &Therapy. 2010; 4: 131–138.

Bonner J., Lloyd P., Lowe P., Lowe P., Golor G. PK/PD, safety and tolerability of a human anti–IL–1β monoclonal antibody (ACZ885) in healthy subjects. Annual Congress of the European Respiratory Society. 2006. Abstract 748.

Lachmann H., Kone–Paut I., Kuemmerle–Deschner G.B., Leslie K.S., Hachulla E., Quartier P., Gitton X., Widmer A. Use of canakinumab in the cryopyrin associated periodic syndrome. N. Engl. J. Med. 2009; 360: 2416–2425.

Kuemmerle–Deschner J.B., Hachulla E., Gartwright R., Hawkins P.N., Tran T.A., Bader–Meunier B., Hoyer J., Gattorno M., Gul A., Smith J., Leslie K.S., Jiménez S., Morell–Dubois S., Davis N., Patel N., Widmer A., Preiss R., Lachmann H.J. Two year results from an open label, multicentre, phase III study evaluating the safety and efficacy of Canakinumab in pts with cryopyrin associated periodic syndrome across different severity phenotypes. Ann. Rheum. Dis. 2011; 70 (12): 2095–2102.

Goldbach–Mansky R., Sibley C., Felix S., Dailey N.J., Canna S.W., Gelabert A., Jones J., Rubin B.I. Efficacy and safety of canacinumab in patients with NOMID/CINCA. Ann. Rheum. Dis. 2012; 71 (suppl.3): 291.

Caorsi R., Lepore L., Zulian F., Alessio M., Stabile A., Insalaco A., Finetti M., Battagliese A., Martini G., Bibalo C., Martini A., Gattorno M. The schedule of administration of Canakinumab in cryopyrin associated periodic syndrome is driven by the phenotype severity rather than the age. Arthritis Res. Ther. 2013; 15 (1): 33.

Hoffman H., Kuemmerle–Deschner J., Hawkins P. et al. Safety of canacinumab in a large cohort of patients with cryopirin associated periodic syndrome: results from the confident registry. Arthritis Rheum. 2012; 64 (10): 78.

Galon J., Aksentijevich I., Mc Dermott F., O`Shea J.J., Kastner D.L. TNFRSF1A mutations and autoinflammatory syndromes. Curr. Opin. Immunol. 2000; 12: 479–486.

Williamson L.M., Hull D., Mehta R., Reeves W.G., Robinson B.H., Toghill P.J. Familial Hibernian fever. Q. J. Med. 1982; 51: 469–480.

Lachmann H.J., Papa R., Gerhold K., Obici L., Touitou I., Cantarini L., Frenkel J., Anton J., Kone–Paut I., Cattalini M., Bader–Meunier B., Insalaco A., Hentgen V., Merino R., Modesto C., Toplak N., Berendes R., Oze, S., Cimaz R., Jansson A., Brogan P.T., Hawkins P.N., Ruperto N., Martini A., Woo P., Gattorno M. The phenotype of TNF receptor-associated autoinflammatory syndrome (TRAPS) at presentation: a series of 158 cases from the Eurofever/EUROTRAPS international registry. Ann. Rheum. Dis. 2014; 73: 2160–2167. doi: 10.1136/annrheumdis-2013-204184368.

Aksentijevich I., Galon J., Soares M., Mansfield E., Hull K., Oh H.H., Goldbach–Mansky R. The tumor necrosis factor receptor associated periodic syndrome: new mutations in TNFRSF1A, ancestral origins, genotype-phenotype studies, and evidence for further genetic heterogeneity of periodic fevers. Am. J. Hum. Genet. 2001; 692: 301–314.

Drenth G., van der Meer G.W. Hereditary Periodic fever. New Engl. J. of med. 2001: 345: 1748–1757.

Jesus A.A., Goldbach–Mansky R. Monogenic autoinflammatory diseases: concept and clinical manifestations. Clin. Immunol. 2013; 147 (3): 155–174. doi:10.1016/j.clim.2013.03.016

Cantarini L., Lucherini O.M., Muscari I., Frediani B., Galeazzi M., Brizi M.G., Simonini G, Cimaz R. Tumor necrosis factor receptor — associated syndrome (TRAPS): State of the art and future perspectives. Autoimmunity Rev. 2012; 12: 38–43. DOI 10.1016/j.autrev.2012.07.020

Aganna E., Hammond L., Hawkins P.N. et al. Heterogeneity among patients with tumor necrosis factor receptor-associated periodic syndrome phenotypes. Art. Rheum. 2003; 48: 2632–2644.

Aksentijevich I., Galon J., Soares M., Mansfield E., Hull K., Oh H.H., Goldbach–Mansky R. The tumor-necrosis-factor receptor-associated periodic syndrome: new mutations in TNFRSF1A, ancestral origins, genotype-phenotype studies, and evidence for further genetic heterogeneity of periodic fevers. Am. J. Hum. Genet. 2001; 692: 301–314.

Caso F., Rigante D., Vitale A., Lucherini O.M., Costa L., Atteno M., Compagnone A., Caso P., Frediani B., Galeazzi M., Punzi L., Cantarini L. Monogenic autoinflammatory syndromes: state of the art on genetic, clinical, and therapeutic issues. Intern. J. of Rheum. 2013; 2013: 513782. DOI 10.1155/2013/513782.

Dode C., Cuisset L., Delpech M., Grateau G. TNFRSF1A associated periodic syndrome (TRAPS), Muckle–Wells syndrome (MWS) and renal amyloidosis. J. Nephrol. 2003; 16: 435–437.

Hull K.M., Drewe E., Aksentijevich I., Singh H.K., Wong K., McDermott E.M., Dean J., Powell R.J., Kastner D.L. The TNF receptor associated autoinflammatory syndrome (TRAPS): emerging concepts of an autoinflammatoty disorders. Medicine (Baltimore). 2002; 81: 349–368.

Bulua A.C., Mogul D.B., Aksentijevich I., Singh H., He D.Y., Muenz L.R., Ward M.M., Yarboro C.H., Kastner D.L., Siegel R.M., Hull K.M. Efficacy of Etanercept in the Tumor Necrosis Factor Receptor — Associated Periodic Syndrome: A Prospective Open Label, Dose Escalation Study. Artritis Rheum. 2012; 64: 908–913. doi: 10.1002/art.33416

Caorsi R., Federici S., Gattorno M. Biologic drugs in autoinflammatory syndromes. Autoimmunity Rev.2012; 12: 81–86.

Gattorno M., Obici L., Meini A., Tormey V., Abrams K., Davis N., Andrews C., Lachmann H.J. Efficacy and safety of Canakinumab in patients with TNF receptor associated periodic syndrome. Arthritis Rheum. 2012; 64 (10): 322.

Brizi M.G., Galeazzi M., Lucherini O.M., Cantarini L., Cimaz R. Successful treatment of tumor necrosis factor receptor-associated periodic syndrome with canacinumab. Ann. of Intern. Med. 2012; 156 (12): 907–908.

The authors declare that there are no conflicts of interest present.